双能CT虚拟平扫对肾脏病变定性的影响

正摘要双能(DE)CT可从单时相对比剂CT增强检查中重建虚拟非对比剂(VNC)影像,这样可能减少多时相CT增强对肾脏病变定性的需求。然而,关于VNC影像用于诊断肾     

静脉血栓栓塞症风险评估模型研究进展与启示

通过文献研究，总结国内外静脉血栓栓塞症各类评估工具的优缺点及适用范围。指出我国与欧美国家人群存在种族、疾病谱和遗传因素等方面的差异，国外量表所纳入的危险因素并不一定能准确、完整地反映我国患者的风险状况。应借鉴国外评估工具的构建方法，基于我国VTE患者数据进行多中心、大样本的回顾性研究，从而构建更适合我国人群的、更准确的VTE风险评估模型。     

Prosthetic urology:past,present,and future

The global population is collectively getting older,and age is directly correlated with erectile dysfunction(ED).With the advent of effective oral agents and wide availability of the Internet,a larger portion of the population is becoming aware of the different treatment options for men with ED.     

评估CT和MRI判断IPMN良恶性的价值

<正>背景胰腺导管内乳头状黏液瘤(IPMN)是由胰腺导管内产生黏液的上皮细胞呈乳头状增殖形成的肿瘤,该肿瘤具有癌变的风险且肿瘤的治疗与IPMN性质密切相关,因此IPMN恶变预测尤为重要,目前尚缺乏研究计算机断层扫描(CT)和磁共振成像(MRI)在IPMN诊断中价值。方法 2011年9月到2013年9月韩国蔚山大学医学收治经病理证实IPMN280例,158例术前均行CT和MRI检查且经手术病理证实     

双能CT碘基图:用于评估胸膜癌病

正摘要目的评估能谱CT在鉴别非钙化性良性胸膜病变和胸膜癌的作用。材料与方法本项为回顾性研究,对2016年6月1日—2018年7月1日期间经组织病理学或影像检     

美国≥65岁女性的数字二维乳腺摄影与断层成像对比

正摘要虽然乳腺癌的发病率和死亡率随着年龄的增长而增加,但有关老年妇女筛查乳腺X线检查的益处和风险,以及老年妇女二维数字乳腺X线摄影(DM)和数字乳腺断层成     

Hollow fiber-based liquid phase microextraction followed by analytical instrumental techniques for quantitative analysis of heavy metal ions and pharmaceuticals

Hollow-fiber liquid-phase microextraction(HF-LPME)and electromembrane extraction(EME)are miniaturized extraction techniques,and have been coupled with various analytical instruments for trace analysis of heavy metals,drugs and other organic compounds,in recent years.HF-LPME and EME provide high selectivity,efficient sample cleanup and enrichment,and reduce the consumption of organic sol-vents to a few micro-liters per sample.HF-LPME and EME are compatible with different analytical in-struments for chromatography,electrophoresis,atomic spectroscopy,mass spectrometry,and electrochemical detection.HF-LPME and EME have gained significant popularity during the recent years.This review focuses on hollow fiber based techniques(especially HF-LPME and EME)of heavy metals and pharmaceuticals(published 2017 to May 2019),and their combinations with atomic spectroscopy,UV-VIS spectrophotometry,high performance liquid chromatography,gas chromatography,capillary elec-trophoresis,and voltammetry.     

健脾益肾方对非小细胞肺癌细胞体外增殖凋亡作用的实验研究

目的:探讨健脾益肾方对非小细胞肺癌(NSCLC)细胞体外增殖凋亡的作用。方法:人NSCLC细胞系A549分为四组:空白对照组(仅加入细胞培养液)、阴性对照组(加入细胞,不进行中药处理)、实验组(加细胞加中药处理)。荧光定量PCR和Western blot分别检测Survivin、Bcl-2和Caspase-3的mRNA和蛋白表达。MTT检测细胞增殖;流式细胞术检测细胞凋亡。结果:与空白对照组相比,阴性对照组细胞在24、48、72 h的吸光度值明显升高,细胞凋亡率下降,Survivin和Bcl-2 mRNA和蛋白相对表达量上调,Caspase-3 mRNA和蛋白相对表达量下调,组间比较差异有统计学意义(P<0.05);而健脾益肾方处理的实验组24、48、72 h的吸光度值均显著降低,细胞凋亡率显著上升,Survivin和Bcl-2 mRNA和蛋白相对表达量下调,Caspase-3 mRNA和蛋白相对表达量上调,与空白对照组相比差异有统计学意义(P<0.05)。结论:健脾益肾方可通过下调Survivin和Bcl-2、上调Caspase-3表达诱导NSCLC细胞凋亡,并抑制肿瘤细胞的增殖,进而抑制NSCLC的发展。     

Fixed bimonthly aflibercept in naïve and switched neovascular age-related macular degeneration patients: one year outcomes

AIM: To determine real life clinical outcomes in poorly responsive and treatment-naïve neovascular age related macular degeneration (nvAMD) patients using bimonthly fixed dosing aflibercept regimen. METHODS: This was a retrospective study of 165 eyes with nvAMD started on aflibercept at Southampton Eye Unit between June 2013 and June 2014. Patients were either switched from pro re nata (PRN) ranibizumab/bevacizumab due to poor response (107 eyes), or treatment-naïve (58 eyes). Patients initially received 3-monthly intravitreal aflibercept injections followed by 2-monthly fixed doses. Clinic visits were scheduled at month 0, 4, 10 and 12. Mean change in best-corrected visual acuity (BCVA) and central retinal thickness (CRT) from baseline were assessed using the Wilcoxon signed-rank test. The proportion of patients maintaining BCVA (<15 letters loss) at 12mo was also evaluated. RESULTS: Mean BCVA change at month 12 was +3.29 and +4.67 letters in the switched and naïve aflibercept groups respectively (P<0.01). BCVA was maintained in 95.3% of switched and 96.6% of naïve patients. CRT at month 12 showed a decrease of -6.16 µm in the switched group and -35.36 µm in the naïve group (P<0.01). Patients previously treated with ranibizumab/bevacizumab had on average received 7.4 ranibizumab/bevacizumab injections over 12.6mo, attending 10 clinic visits. The fixed dosing aflibercept regimen required an average of 7.1 injections (naïve group), 7.5 injections (switched group) and 4 clinic visits per year. CONCLUSION: Fixed bimonthly aflibercept is effective in both treatment-naïve and poorly responsive nvAMD patients. Adopting a fixed dosing regimen can reduce patient burden without compromising on outcomes.